Radiopharm Theranostics Limited (NASDAQ:RADX) Filings

Radiopharm Theranostics Limited

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
RAD interim analysis at SNO26 on RAD101 Phase IIb dataNov 15, 2026Other filingsASX
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
Change of Director's Interest Notices x 4Nov 10, 2026Ownership change noticeASX
6-K · Report of a foreign issuerNov 4, 2026Current reportSEC
RAD Alignment with US FDA for Development of RAD101Nov 3, 2026Other filingsASX
6-K · Report of a foreign issuerOct 30, 2026Current reportSEC
Quarterly Activities/Appendix 4C Cash Flow ReportOct 30, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 30, 2026Quarterly reportASX
4 · Change in ownershipOct 27, 2026Insider tradeSEC
6-K · Report of a foreign issuerOct 27, 2026Current reportSEC
Notice of Annual General Meeting/Proxy FormOct 26, 2026Meeting noticeASX
6-K · Report of a foreign issuerOct 26, 2026Current reportSEC
Radiopharm receives $8M advance on FY26 R&D tax incentiveOct 26, 2026Other filingsASX
6-K · Report of a foreign issuerOct 20, 2026Current reportSEC
Notification regarding unquoted securities - RADOct 20, 2026Other filingsASX
Change of Director's Interest Notices x 4Oct 20, 2026Ownership change noticeASX
Notification of cessation of securities - RADOct 20, 2026FinancingASX
SCHEDULE 13G · Big-stake noticeOct 14, 2026Big-stake noticeSEC
Non-Compliance with Listing Rule 10.11Oct 11, 2026Legal or regulatory actionASX
6-K · Report of a foreign issuerOct 5, 2026Current reportSEC
RAD Completes Meeting with US FDA for Development of RAD101Oct 4, 2026Other filingsASX
6-K · Report of a foreign issuerOct 1, 2026Current reportSEC
Notification of cessation of securities - RADOct 1, 2026FinancingASX
Change of Director's Interest Notice (RC)Oct 1, 2026Ownership change noticeASX
20-F · Annual reportSep 30, 2026Annual reportSEC
6-K · Report of a foreign issuerSep 30, 2026Current reportSEC
Appendix 4G and Corporate Governance StatementSep 30, 2026Other filingsASX
Annual Report and Form 20-FSep 30, 2026Annual reportASX
EFFECT · Notice that a registration is effectiveSep 24, 2026Other filingsSEC
424B3 · ProspectusSep 23, 2026Offer documentSEC
6-K · Report of a foreign issuerSep 22, 2026Current reportSEC
Change of Director's Interest Notices x 4Sep 22, 2026Ownership change noticeASX
Notification regarding unquoted securities - RADSep 16, 2026Other filingsASX
RADOC New Class Options Range of Units and Top 20 HoldersSep 16, 2026Securities holder registration reportASX
Application for quotation of securities - RADSep 16, 2026FinancingASX
Application for quotation of securities - RADSep 16, 2026FinancingASX
Share purchase plan completedSep 16, 2026FinancingASX
6-K · Report of a foreign issuerSep 14, 2026Current reportSEC
F-3 · Registration statementSep 14, 2026Offer documentSEC
RAD oral presentation at SNO26 on RAD101 Phase IIb dataSep 13, 2026Other filingsASX
6-K · Report of a foreign issuerSep 11, 2026Current reportSEC
Results of MeetingSep 10, 2026Meeting outcomeASX
6-K · Report of a foreign issuerSep 9, 2026Current reportSEC
RAD Announces Positive Data from RAD301 P1 Imaging TrialSep 8, 2026Other filingsASX
SCHEDULE 13G · Big-stake noticeSep 4, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeSep 4, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerAug 28, 2026Current reportSEC
Appendix 4E and Preliminary Final ReportAug 28, 2026ResultsASX
6-K · Report of a foreign issuerAug 27, 2026Current reportSEC
Change of Director's Interest Notices x 4Aug 27, 2026Ownership change noticeASX
6-K · Report of a foreign issuerAug 26, 2026Current reportSEC
RAD Doses First Patient in Second Cohort of BetaBart (RV-01)Aug 25, 2026Other filingsASX
Ceasing to be a substantial holderAug 24, 2026Ownership change noticeASX
6-K · Report of a foreign issuerAug 20, 2026Current reportSEC
RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT TrialAug 19, 2026Other filingsASX
6-K · Report of a foreign issuerAug 17, 2026Current reportSEC
Change in substantial holdingAug 17, 2026Ownership change noticeASX
RAD to meet with US FDA to align on RAD 101 Phase 3 TrialAug 16, 2026Other filingsASX
6-K · Report of a foreign issuerAug 13, 2026Current reportSEC
Notice of Extraordinary General Meeting and Proxy FormAug 12, 2026Proxy formASX
Share Purchase Plan - Now OpenAug 6, 2026FinancingASX
Update - Proposed issue of securities - RADAug 4, 2026FinancingASX
6-K · Report of a foreign issuerAug 3, 2026Current reportSEC
Application for quotation of securities - RADAug 2, 2026FinancingASX
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
Quarterly Activities/Appendix 4C Cash Flow ReportJul 30, 2026Quarterly reportASX
Change in substantial holdingJul 30, 2026Ownership change noticeASX
Target market determination (TMD)Jul 30, 2026Other filingsASX
ProspectusJul 30, 2026Offer documentASX
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
Notice Under Section 708AJul 28, 2026Other filingsASX
Application for quotation of securities - RADJul 27, 2026FinancingASX
6-K · Report of a foreign issuerJul 27, 2026Current reportSEC
424B5 · ProspectusJul 27, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 24, 2026Current reportSEC
RAD completes A$12.5 M placement and launches A$6 M SPPJul 24, 2026FinancingASX
424B5 · ProspectusJul 23, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 22, 2026Current reportSEC
RAD Achieves Partial Response in Phase 1 Trial of RAD204Jul 21, 2026ResultsASX
6-K · Report of a foreign issuerJul 6, 2026Current reportSEC
6-K · Report of a foreign issuerJun 30, 2026Current reportSEC
6-K · Report of a foreign issuerJun 3, 2026Current reportSEC
3 · Initial statement of ownershipMay 6, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 6, 2026Insider tradeSEC
6-K · Report of a foreign issuerMay 1, 2026Current reportSEC
3 · Initial statement of ownershipApr 30, 2026Insider tradeSEC
6-K · Report of a foreign issuerApr 23, 2026Current reportSEC
6-K · Report of a foreign issuerApr 20, 2026Current reportSEC
6-K · Report of a foreign issuerApr 16, 2026Current reportSEC
RAD Completes Enrollment in Phase 2b Trial of RAD 101Apr 15, 2026Operations updateASX
6-K · Report of a foreign issuerApr 8, 2026Current reportSEC
RAD202 Phase 1 HEAT Trial Advances to Dose Level 3Apr 7, 2026Other filingsASX
6-K · Report of a foreign issuerApr 7, 2026Current reportSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 27, 2026Current reportSEC
RAD Doses First Patient in RAD 402 Phase 1 Clinical StudyMar 26, 2026Operations updateASX
6-K · Report of a foreign issuerMar 24, 2026Current reportSEC
RAD101 2nd interim Ph.2b data - 90% achieve primary endpointMar 23, 2026ResultsASX
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerFeb 27, 2026Current reportSEC
Half Year Report and Appendix 4D 31 December 2025Feb 27, 2026Interim reportASX
6-K · Report of a foreign issuerFeb 24, 2026Current reportSEC
RAD Doses First Patient in 177Lu-BetaBart (RV-01) StudyFeb 23, 2026Operations updateASX
6-K · Report of a foreign issuerJan 28, 2026Current reportSEC
Quarterly Activities/Appendix 4C Cash Flow ReportJan 27, 2026Quarterly reportASX
SCHEDULE 13G/A · Big-stake notice, amendedJan 16, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJan 12, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 8, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveDec 29, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveDec 29, 2025Other filingsSEC
424B3 · ProspectusDec 23, 2025Offer documentSEC
424B5 · ProspectusDec 23, 2025Offer documentSEC
CORRESP · Letter to the SECDec 19, 2025Other filingsSEC
CORRESP · Letter to the SECDec 19, 2025Other filingsSEC
6-K · Report of a foreign issuerDec 19, 2025Current reportSEC
F-3 · Registration statementDec 17, 2025Offer documentSEC
F-3 · Registration statementDec 16, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 15, 2025Current reportSEC
RAD101 interim Phase 2b data - 92% achieve primary endpointDec 14, 2025Other filingsASX
20-F/A · Annual report, amendedDec 10, 2025Annual reportSEC
6-K · Report of a foreign issuerDec 3, 2025Current reportSEC
6-K · Report of a foreign issuerNov 25, 2025Current reportSEC
6-K · Report of a foreign issuerNov 20, 2025Current reportSEC
6-K · Report of a foreign issuerNov 19, 2025Current reportSEC
6-K · Report of a foreign issuerNov 18, 2025Current reportSEC
RAD Approval for Phase 1 Therapeutic Trial of RAD 402Nov 17, 2025Other filingsASX
6-K · Report of a foreign issuerNov 17, 2025Current reportSEC
RAD Announces 50% Enrollment in Phase 2b Trial of RAD101Nov 16, 2025Other filingsASX
6-K · Report of a foreign issuerNov 12, 2025Current reportSEC
RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204Nov 11, 2025Operations updateASX
6-K · Report of a foreign issuerNov 4, 2025Current reportSEC
6-K · Report of a foreign issuerNov 3, 2025Current reportSEC
6-K · Report of a foreign issuerOct 28, 2025Current reportSEC
6-K · Report of a foreign issuerOct 22, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
ProspectusOct 20, 2025Offer documentASX
RAD completes A$35 M Placement and launches A$5 M SPPOct 19, 2025FinancingASX
Trading HaltOct 15, 2025Trading halt or suspensionASX
6-K · Report of a foreign issuerOct 7, 2025Current reportSEC
6-K · Report of a foreign issuerOct 1, 2025Current reportSEC
Radiopharm received approval for RAD 202 trial accelerationSep 30, 2025Other filingsASX
SPL:Research & Option Agreement with Radiopharm TheranosticsSep 30, 2025Other filingsASX
6-K · Report of a foreign issuerSep 29, 2025Current reportSEC
20-F · Annual reportSep 17, 2025Annual reportSEC
6-K · Report of a foreign issuerSep 17, 2025Current reportSEC
6-K · Report of a foreign issuerSep 15, 2025Current reportSEC
6-K · Report of a foreign issuerAug 29, 2025Current reportSEC
Appendix 4E and Preliminary Final ReportAug 29, 2025ResultsASX
6-K · Report of a foreign issuerAug 21, 2025Current reportSEC
6-K · Report of a foreign issuerAug 1, 2025Current reportSEC
6-K · Report of a foreign issuerJul 29, 2025Current reportSEC
6-K · Report of a foreign issuerJul 28, 2025Current reportSEC
RAD receives IND approval from US FDA for Betabart (RV-01)Jul 27, 2025Other filingsASX
SCHEDULE 13G · Big-stake noticeJul 23, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJul 21, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJul 16, 2025Current reportSEC
6-K · Report of a foreign issuerJun 23, 2025Current reportSEC
6-K · Report of a foreign issuerJun 12, 2025Current reportSEC
RAD Granted US FDA Fast Track for RAD101 Metastases ImagingJun 10, 2025Other filingsASX
6-K · Report of a foreign issuerJun 10, 2025Current reportSEC
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Jun 3, 2025Other filingsASX
6-K · Report of a foreign issuerJun 3, 2025Current reportSEC
6-K · Report of a foreign issuerJun 2, 2025Current reportSEC
RAD Reports Positive Preclinical Lu177-B7H3-mAb DataJun 1, 2025Operations updateASX
6-K · Report of a foreign issuerMay 30, 2025Current reportSEC
6-K · Report of a foreign issuerMay 19, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
Acceleration of RAD204 Phase 1 dose escalation trialMay 11, 2025Other filingsASX
6-K · Report of a foreign issuerApr 29, 2025Current reportSEC
6-K · Report of a foreign issuerApr 28, 2025Current reportSEC
First patient dosed in Phase IIb imaging for Brain MetsApr 27, 2025Operations updateASX
6-K · Report of a foreign issuerMar 17, 2025Current reportSEC
New RAD202 data confirms positive tumor uptakeMar 16, 2025Other filingsASX
6-K · Report of a foreign issuerMar 13, 2025Current reportSEC
6-K · Report of a foreign issuerMar 7, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2025Current reportSEC
Half Year Report and Appendix 4D 31 December 2024Feb 28, 2025Interim reportASX
6-K · Report of a foreign issuerFeb 25, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 24, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 10, 2025Current reportSEC
Clinical trial data shows RAD 101 detects Brain MetastasesFeb 9, 2025Other filingsASX
6-K · Report of a foreign issuerJan 30, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 29, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJan 21, 2025Current reportSEC
6-K · Report of a foreign issuerJan 10, 2025Current reportSEC
Lantheus increases shareholding in RAD with A$8m placementJan 9, 2025FinancingASX
6-K · Report of a foreign issuerDec 30, 2024Current reportSEC
Strategic Co-Development Partnership with Lantheus for AusDec 29, 2024Other filingsASX
6-K · Report of a foreign issuerDec 20, 2024Current reportSEC

This page holds 200 of 290 filings.

All of its filings on SEC EDGAR